1
|
Fife D, Feng Y, Wang MYH, Chang CJ, Liu CY, Juang HT, Furnback W, Singh J, Wang B. Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Res 2017; 252:277-283. [PMID: 28288438 DOI: 10.1016/j.psychres.2017.03.006] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2016] [Revised: 03/04/2017] [Accepted: 03/05/2017] [Indexed: 12/28/2022]
Abstract
Epidemiologic data on treatment resistant depression (TRD) in Asia-Pacific countries are limited. We estimated the incidence of TRD in Taiwan using a cohort of 704,265 adults randomly sampled from Taiwan's National Health Insurance Research database for 2005. TRD was defined as a patient having pharmaceutically treated depression (PTD) not adequately responding to 2 antidepressant (AD) regimens, i.e., AD regimens that were followed by other AD regimens. Among 2751 PTD subjects, 576 (20.94%, 95% CI: 19.46, 22.49) developed TRD, a proportion similar to that in North American studies. TRD incidence was 0.82 (95% CI: 0.75, 0.89) cases /1000 population in 2005, increased with age, and was higher in females than in males. SSRI's were the most frequently used ADs. Augmentation with antipsychotics was common. The median time from PTD onset (first AD medication) to TRD onset was 416 days but psychiatrists practicing in Taiwan indicated they would switch within <=3 months if an AD medication was not effective. We therefore repeated the analysis with a 6 months cap on time from onset of PTD to TRD. In this supplemental, post-hoc, analysis, 68 PTD subjects, 2.47%, (95% CI: 1.94, 3.10) developed TRD; i.e., 0.10 (95% CI: 0.08, 0.12) incident cases/1000 population.
Collapse
Affiliation(s)
- Daniel Fife
- Department of Epidemiology, Janssen Pharmaceutical Research and Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA.
| | - Yu Feng
- Janssen (China) Research and Development Center, a division of Johnson & Johnson (China) investment, Ltd, Jian Guo Lu, Beijing 100025, People's Republic of China.
| | - Michael Yao-Hsien Wang
- Department of Psychiatry, Buddhist Tzu-Chi General Hospital, Taipei Branch, New Taipei City, Taiwan.
| | - Chee-Jen Chang
- Graduate Institute of Clinical Medical Science, Chang Gung University, 259 Wen-Hwa 1st Road, Kwei-Shan, Tao-Yuan 333, Taiwan.
| | - Chia-Yih Liu
- Department of Psychiatry, Chang Gung Memorial Hospital, 5 Fu-Shin Street, Kwei-Shan, Tao-Yuan 33305, Taiwan.
| | - Hsiao-Ting Juang
- Biostatistical Center for Clinical Research, Chang Gung Memorial Hospital, 5 Fu-Shin Street, Kwei-Shan, Tao-Yun 33305, Taiwan.
| | - Wesley Furnback
- Elysia Group, Ltd., Xiamen St., Lane 113, No. 17-1, Floor 2, Taipei, Taiwan.
| | - Jaskaran Singh
- Clinical Research, Janssen Pharmaceutical Research and Development, LLC 3210 Merryfield Row, San Diego, CA 92121, USA.
| | - Bruce Wang
- Elysia Group, Ltd., Xiamen St., Lane 113, No. 17-1, Floor 2, Taipei, Taiwan.
| |
Collapse
|